OBJECTIVE:To evaluate the therapeutic efficacy of high-dose Methylprednisolone plus Batroxobin Injection for sudden deafness(SD).METHODS:62 SD cases(66 ears) were randomly assigned to receive conventional therapy alone (control group,32 cases/34 ears) or conventional therapy in combination with high - dose Methylprednisolone(trial group,n= 30 cases/32 ears) for 12 days.The clinical efficacy was compared between the two groups.RESULTS:The total effective rate of the trial group vs.the control group was 93.75%vs.76.47%(P

OBJECTIVE: To evaluate the efficacy of intratympanic dexamethasone injection for the moderate and severe sudden deafness with BPPV. METHOD: A total of 63 patients diagnosed with sudden sensorineural hearing loss with BPPV were treated through OPD. Patients were divided into three groups: 20 cases in intratympanic dexamethasone injection as initial treatment (group A); 18 cases in systemic hormone therapy group (group B); 25 cases in intratympanic dexamethasone injection as salvage treatment (group C). In addition, routine drugs were used to all patients. RESULT: The overall effective rate of group A, B and C in hearing recovery was 60.0%, 38.9% and 48.0%, respectively: (1) No significant difference of hearing recovery was observed among three groups (P > 0.05); (2) A significant difference of hearing recovery was evidenced between group A and C (P < 0.05); (3) A significant difference of hearing recovery was evidenced between group A and C (P < 0.05); (4) No statistically significant difference was found in the hearing recovery between group B and C (P > 0.05). CONCLUSION Our data showed that intratympanic dexamethasone should be used as initial therapy for treating the moderate and severe sudden deafness with BPPV.
Benign Paroxysmal Positional Vertigo ; complications ; Dexamethasone ; administration & dosage ; therapeutic use ; Hearing Loss, Sensorineural ; complications ; drug therapy ; Hearing Loss, Sudden ; complications ; drug therapy ; Hearing Tests ; Humans ; Injection, Intratympanic ; Salvage Therapy ; Treatment Outcome

OBJECTIVE: To investigate the prognosis of sudden deafness patients with benign paroxysmal positional vertigo (BPPV). METHOD: The clinical data of 24 sudden deafness patients with BPPV was analyzed. The outcome of 125 sudden deafness patients without BPPV at the same time was compared. RESULT: Hearing improvement after three months treatment was 41.67% and 72.80% in sudden deafness patients with BPPV and sudden deafness patients without BPPV, respectively. The difference was statistically significant (P<0.05). CONCLUSION The prognosis of hearing in sudden deafness patients with BPPV is worse than that in sudden deafness patients without BPPV. BPPV may predict a poor hearing outcome in sudden deafness.
Adolescent ; Adult ; Aged ; Benign Paroxysmal Positional Vertigo ; complications ; diagnosis ; Female ; Hearing Loss, Sudden ; complications ; diagnosis ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Young Adult

Objective To investigate the familial incidence of multiple primary carcinoma in Chinese hereditary nonpolyposis colorectal cancer patients (HNPCC) in Northeast China.Methods By family line investigation,multiple primary carcinoma (MPC) spectrum' s characteristics of 509 patients in 85 families registered in strict conformity with the HNPCC Amsterdam criteria Ⅱ were analyzed retrospectively.Results Of the 85 HNPCC families,multiple primary carcinoma developed in 55 patients in 25 families,among them 45 patients had metachronous carcinoma in 17 families,16 patients had synchronous carcinoma occurred in 12 families,6 patients with both synchronous carcinoma and metachronous carcinoma in 4 families.Conclusions Multiple primary carcinoma developed in significantly high incidence in Northeast China in Chinese hereditary nonpolyposis colorectal cancer patients,the most common MPC are colorectal cancer and endometrial cancer.

Objective To evaluate the efficiency of monitoring parameters and methods of immunosuppresive treatment in intestinal transplantation and to provide scientific evidence for establishment of Intestinal Transplant Registry.Methods The data of 15 patients receiving intestinal transplantation between 1994 and 2009 were analyzed retrospectively for one year. The patients were fallen into 3 eras (1994-1995, 2003-2006, 2007-2009) according to different immunosuppresive strategies. The perioperative status and one-year survival rate were followed up. The monitoring frequency of implications of intestinal transplantation, such as rejection, infection, toxic and side-effects, was evaluated. The monitoring parameters were examined in the proportion of lymphocytes, concentration of tacrolimus, and function of the liver and kidney during a follow-up period of one year.Results During 1994-1995 and 2003-2006, the survival time of grafts was under one year. During 2007-2009, the 6-month and one-year survival rate in 5 patients (grafts) was 100% and 83.33% respectively; The increased frequency of rejection occurred during 7 to 12 months after operation; The closure of abdominal stoma was postponed from postoperative six months to one year; Asymptomatic mild rejection after operation was examined (10/13, 76.92%).Conclusion During one year postoperation, monitoring methods, parameters and frequency for immunosuppressive treatment in intestinal transplantation are rational, and may monitor the disease conditions of the patients.

OBJECTIVETo observe the pathological changes in the myocardial and pulmonary tissues in miniature pigs with chronic pulmonary hypertension induced by monocrotaline (MCT).

METHODSTwelve male miniature pigs (weigh 15.0-18.0 kg, aged 4.0-4.5 months) were examined for baseline mean pulmonary artery pressure (mPAP), followed by intraperitoneal injection of 10.0 mg/kg MCT in 10 randomly selected pigs. The mean pulmonary artery pressure at 4 and 8 weeks were determined, and the pathological changes in the myocardial and pulmonary tissues were observed.

RESULTSThe baseline mPAP of normal miniature pigs was 15.19∓0.70 mmHg. At 4 and 8 weeks after MCT injection, the sPAP and dPAP were 19.69∓2.47 mmHg and 25.62∓4.88 mmHg, respectively, and the mPAP increased significantly compared with that of the normal control group (P<0.01). Obvious pathological changes such as pulmonary hypertension and right ventricular hypertrophy were found in the pigs 4 weeks after MCT injection, and at 8 weeks, significant pathological changes occurred including right ventricular fibrosis and thickening of the tunica media of the pulmonary artery.

CONCLUSIONMCT can cause pulmonary hypertension in miniature pigs 8 weeks after drug administration, shown as increased pulmonary artery pressure and pulmonary vascular remodeling.

Animals ; Hypertension, Pulmonary ; chemically induced ; pathology ; Lung ; pathology ; Male ; Monocrotaline ; adverse effects ; Myocardium ; pathology ; Swine ; Swine, Miniature

Objective:To evaluate the effects of cellulift ? administered intradermally by mesotherapy on collagen synthesis in D-galactose induced aging model of rats. Methods:The study was conducted between April and October in 2014 in the Department of Anatomy, Qindao University. 30 male rats were randomly allocated to three groups: aging treatment group, aging control group and normal group; each group had ten rats. Aging treatment group and the control group were subcutaneously injected with D-galactose prepared in saline 125 mg·kg -1·d -1 for 42 day. Normal group was injected with saline for 42 d with same method and dose. From the 18th day after shaving their hair, the dermis of two sides hip skin marked zone of aging treatment group were injected cellulift at a dose of 1 ml per week for 4 weeks. Meanwhile, the aging control group was administrated the same volume of saline with same method. In vivo skin collagen alterations were investigated by reflectance confocal microscopy 3 days after every treatment. Skin specimens were obtained in 42 days. In order to measure the dermal collagen density and dermal thickness, HE and Masson trichrome staining were performed, respectively. Immunohistochemical staining for TGFβ1 and proliferating cell nuclear antigen (PCNA) was performed. Also, the level of TGFβ1, Smad3, types Ⅰ and Ⅲ pro-collagen mRNA expression was assessed by real-time quantitative polymerase chain reaction. Results:As revealed by RCM, collagen density of aging treatment group increased gradually after treatments, while in aging control group it decreased with time. Measurement of dermal thickness, hydroxyproline content and TGFβ-1 mRNA and protein expression in treatment group increased significantly as compared with that in aging control group, but were significantly lower than that in normal group (F values were 25.45, 98.90, 37.94 and 21.35, respectively; P<0.05). Measurement of dermal collagen density, the mRNA expression of type I pre-collagen and Smad3 elevated over that of aging control group with significant difference (F values were 44.46, 29.54 and 10.01, respectively; P<0.05), and there was no difference between normal and aging treatment group ( P>0.05). The difference of PCNA expression between aging control and treatment groups was not significant ( P>0.05), and both were lower than normal group ( P<0.05) . Conclusions:Cellulift ? shows anti-aging effects by activating collagen synthesis and eventually causing dermal thickening. This effect is probably mediated by TGF-β1/Smad3 signaling pathway.

Due to the special physiological and pathological characteristics of gliomas, most therapeutic drugs are prevented from entering the brain. To improve the poor prognosis of existing therapies, researchers have been continuously developing non-invasive methods to overcome barriers to gliomas therapy. Although these strategies can be used clinically to overcome the blood‒brain barrier (BBB), the accurate delivery of drugs to the glioma lesions cannot be ensured. Nano-drug delivery systems (NDDS) have been widely used for precise drug delivery. In recent years, researchers have gathered their wisdom to overcome barriers, so many well-designed NDDS have performed prominently in preclinical studies. These meticulous designs mainly include cascade passing through BBB and targeting to glioma lesions, drug release in response to the glioma microenvironment, biomimetic delivery systems based on endogenous cells/extracellular vesicles/protein, and carriers created according to the active ingredients of traditional Chinese medicines. We reviewed these well-designed NDDS in detail. Furthermore, we discussed the current ongoing and completed clinical trials of NDDS for gliomas therapy, and analyzed the challenges and trends faced by clinical translation of these well-designed NDDS.

Objective: To investigate the current status and real performance of the detection of RUNX1-RUNX1T1 fusion transcript levels and WT1 transcript levels in China through interlaboratory comparison. Methods: Peking University People’s Hospital (PKUPH) prepared the samples for comparison. That is, the fresh RUNX1-RUNX1T1 positive (+) bone morrow nucleated cells were serially diluted with RUNX1-RUNX1T1 negative (-) nucleated cells from different patients. Totally 23 sets with 14 different samples per set were prepared. TRIzol reagent was added in each tube and thoroughly mixed with cells for homogenization. Each laboratory simultaneously tested RUNX1-RUNX1T1 and WT1 transcript levels of one set of samples by real-time quantitative PCR method. All transcript levels were reported as the percentage of RUNX1-RUNX1T1 or WT1 transcript copies/ABL copies. Spearman correlation coefficient between the reported transcript levels of each participated laboratory and those of PKUPH was calculated. Results: ①RUNX1-RUNX1T1 comparison: 9 samples were (+) and 5 were (-) , the false negative and positive rates of the 20 participated laboratories were 0 (0/180) and 5% (5/100) , respectively. The reported transcript levels of all 9 positive samples were different among laboratories. The median reported transcript levels of 9 positive samples were from 0.060% to 176.7%, which covered 3.5-log. The ratios of each sample’s highest to the lowest reported transcript levels were from 5.5 to 12.3 (one result which obviously deviated from other laboratories’ results was not included) , 85% (17/20) of the laboratories had correlation coefficient ≥0.98. ②WT1 comparison: The median reported transcript levels of all 14 samples were from 0.17% to 67.6%, which covered 2.6-log. The ratios of each sample’s highest to the lowest reported transcript levels were from 5.3-13.7, 62% (13/21) of the laboratories had correlation coefficient ≥0.98. ③ The relative relationship of the reported RUNX1-RUNX1T1 transcript levels between the participants and PKUPH was not always consistent with that of WT1 transcript levels. Both RUNX1-RUNX1T1 and WT1 transcript levels from 2 and 7 laboratories were individually lower than and higher than those of PKUPH, whereas for the rest 11 laboratories, one transcript level was higher than and the other was lower than that of PKUPH. Conclusion The reported RUNX1-RUNX1T1 and WT1 transcript levels were different among laboratories for the same sample. Most of the participated laboratories reported highly consistent result with that of PKUPH. The relationship between laboratories of the different transcript levels may not be the same.